By: IPP Bureau
Last updated : August 11, 2025 2:24 pm
Dr. Venkatraman brings over 25 years of experience in small molecule and Biologics drug development, manufacturing, and advancing strategic growth initiatives
LAXAI Life Sciences (LAXAI), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), has appointed Sripathy Venkatraman as Chief Executive Officer.
Dr. Venkatraman brings over 25 years of experience in small molecule and Biologics drug development, manufacturing, and advancing strategic growth initiatives. He most recently served as Head of Global R&D at Curia, where he played a central role in shaping the company’s strategic direction, driving the business unit’s growth across global markets. Sri joined Curia (formerly AMRI) in 2002 and progressed through a series of scientific and leadership roles, culminating in the oversight of the R&D business.
“As our new CEO, Sri not only brings deep scientific and operational expertise, but also a clear strategic vision for LAXAI’s evolution into a global CRDMO partner,” said Vamsi Maddipatla, Chairman of LAXAI Life Sciences. “His experience in scaling complex operations, building high-performance teams, and driving innovation across modalities makes him uniquely qualified to lead LAXAI through its next phase of growth.”
During his tenure at Curia, Sri helped the organization navigate founder-led and private equity transitions, while expanding capabilities in small molecule and emerging therapeutic platforms. His leadership was marked by a strong focus on building scalable platforms, integrating global teams, and fostering a culture of innovation and accountability. With a keen understanding of both technical and commercial drivers, Sri helped position the organization for sustained growth and deeper engagement with biotech and pharmaceutical partners.
“LAXAI’s reputation for scientific excellence, its strong foundation, and the opportunity to shape and grow a differentiated global business is what drew me to this opportunity,” said Dr. Venkatraman. “I’m excited to build on this momentum, expand our global footprint, and invest in capabilities that matter to biotech innovators. Our goal is to become the CRDMO of choice, not just a vendor, but a true scientific partner.”